Boehringer Ingelheim sales grow 2% in first-half 2015

4 August 2015

German family-owned pharma major Boehringer Ingelheim this morning posted first-half 2015 results, showing that group sales rose a modest 2% to around 7.4 billion euros ($8.18 billion) compared with the same period in the previous year.

In euro terms, the company was actually able to increase its net sales by 13%. The euro’s relatively weakness compared to most other currencies led to this very positive development in the conversion, said Boehringer.

The Prescription Medicines business remains stable. The Consumer Health Care and Animal Health businesses in particular performed very well.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK